Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2/PHASE3
INTERVENTIONAL
2008-06-30
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Studies show that topical heparin has, in addition to the already known anticoagulant activity, anti-inflammatory properties, analgesic, and neoangiogenic, stimulating blood flow and increasing the repair of the fabric as well as the restoration of collagen and reepiteliztion. Moreover, the use of heparin reduces the need for painful medical procedures, as debridations, surgeries and transplants The intention of this work is to verify the effectiveness and safety of sodium heparin in the treatment of burns of the skin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heparin for the Treatment of Burn Wound Pain
NCT02497326
Efficacy and Safety of Aluminaid Versus Hydrogel Wound Dressings
NCT03190655
SN514-066b Enzyme in Deep Partial Thickness Burns
NCT06628037
Wound Healing and Pain Management in Partial Thickness Burns
NCT01289340
Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft
NCT06379724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion Criteria
* Patients aged above 12 years who have suffered thermal burns of 2nd degree burns or mixed 2 and 3 degrees in up to 10% of body surface and indication of outpatient treatment.
Exclusion Criteria
* Area burned more than 10% of body surface
* the presence of the 3 rd degree burns
* burns in the face or genitals
* burns in poly-traumatized
* respiratory injury
* disorders of coagulation
* thrombocytopenia
* erosive gastro cases
* clinically relevant bleeding
* hypersensitivity to anticoagulants
* liver disease
* nephropathy
* diabetes
* 35
* serious allergy
* descontrole emotional
* pregnancy
* anemia
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
patients treated with heparin
heparin
patients will receive the application of one of two types of heparin directly on the injured area
2
Patients treated with heparin
heparin
patients will receive the application of one of two types of heparin directly on the injured area
3
patients treated with folder water directly on the injured area
folder water
patients will receive the application of folder water directly on the injured area
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
heparin
patients will receive the application of one of two types of heparin directly on the injured area
heparin
patients will receive the application of one of two types of heparin directly on the injured area
folder water
patients will receive the application of folder water directly on the injured area
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* the presence of the 3 rd degree burns
* burns in the face or genitals
* burns in poly-traumatized
* respiratory injury
* disorders of coagulation
* thrombocytopenia
* erosive gastro cases
* clinically relevant bleeding
* hypersensitivity to anticoagulants
* liver disease
* nephropathy
* diabetes
* 35
* serious allergy
* descontrole emotional
* pregnancy
* anemia
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azidus Brasil
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Azidus Brasil
Principal Investigator Dr. Alexandre Frederico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LAL Clinica PPesquisa e Desenvolvimento
Valinhos, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEPCRI0208
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.